Ticker

MISSISSAUGA, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX), a profitable growth-stage specialty healthcare products company, is pleased to announce that it will be presenting at the upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre (North Building) on Tuesday, April 21st and…

MISSISSAUGA, Ontario, March 24, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 44,222 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company's Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third…

BioSyent Inc. (RX:CA) Q4 2025 Earnings Call Prepared Remarks Transcript

MISSISSAUGA, Ontario, March 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. Key highlights include:

MISSISSAUGA, Ontario, March 12, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 19, 2026 after market hours. A presentation on the Company's fourth quarter and full year 2025 results by René Goehrum, BioSyent President and CEO, will also be available on the…